

GLOBUS MEDICAL INC  
Form 8-K  
June 11, 2014

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): June 5, 2014

GLOBUS MEDICAL, INC.  
(Exact name of registrant as specified in charter)

DELAWARE (State or other jurisdiction of incorporation)	001-35621 (Commission File Number)	04-3744954 (IRS Employer Identification No.)
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA 19403 (Address of principal executive offices) (Zip Code)		
(610) 930-1800 (Registrant's telephone number, including area code)		

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07. Submission of Matters to a Vote of Security Holders.

The Annual Meeting of Stockholders (the “Annual Meeting”) of Globus Medical, Inc. (the “Company”) was held on June 5, 2014. At the Annual Meeting, the stockholders voted on the following three proposals and cast their votes as described below.

Proposal 1

The individuals listed below were each elected at the Annual Meeting to serve a three-year term on the Company's Board of Directors.

Nominee	For	Against	Abstain	Broker Non-Vote
David M. Demski	288,019,048	26,967,921	211,702	13,040,969
Kurt C. Wheeler	313,663,567	1,322,102	213,002	13,040,969

Proposal 2

A proposal to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2014, as described in the Company’s definitive proxy statement on Schedule 14A (the “Proxy Statement”) filed with the Securities and Exchange Commission. This proposal was approved.

For	Against	Abstain	Broker Non-Vote
327,176,072	839,852	223,716	—

Proposal 3

A non-binding advisory vote to approve the compensation of the Company's named executive officers, as described in the Proxy Statement. This proposal was approved.

For	Against	Abstain	Broker Non-Vote
310,323,818	4,631,655	243,198	13,040,969

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GLOBUS MEDICAL, INC.  
(Registrant)

Dated: June 11, 2014

/s/ ANTHONY L. WILLIAMS

Anthony L. Williams  
Senior Vice President of Business Development &  
General Counsel